Another in vitro experiment revealed that ITGB8 promoted gefitinib resistance in hepatic cancer, facilitated the cell cycle and decreased cell apoptosis by interacting with the transforming growth factor β pathway in the HepG2/G cell line (45). The gene discussed is ITGB8; the disease is liver cancer.